Dr. Voros is Chief Scientific Officer, Chief of the Center of Wellness for Prevention and Women's Heart Disease, and Medical Director of the Cardiovascular Magnetic Resonance Imaging and Computed Tomography Division at the Piedmont Heart Institute (PHI) in Atlanta, GA. He oversees all research operations at PHI, which has more than 70 ongoing clinical research studies. In addition, Dr. Voros heads the comprehensive cardiovascular prevention program at PHI, bringing an integrated approach to heart disease by incorporating genetic and genomic medicine, advanced metabolic evaluation, and noninvasive imaging into everyday patient care. As Medical Director for Cardiovascular Magnetic Resonance Imaging and Computed Tomography at PHI, he oversees one of the most active clinical and research imaging programs in the country.

Dr. Voros conducts an active research program in imaging of atherosclerosis using various modalities to investigate the effect of lipid-modifying therapies on atherosclerosis using novel imaging approaches. He is a Principal Investigator on numerous local and national clinical studies in the field of genetics, genomics, and advanced imaging, and has 25 recent publications in his fields of interest.

As Chairman of HemoShear's Scientific Advisory Board, Dr. Voros was instrumental in helping select compounds for HemoShear's proof-of-concept program to validate the technology with known human drug successes and failures.

Dr. Voros received his medical training at the University Medical School of Pecs in Hungary, was Chief Medical Resident at the University of Alabama at Birmingham, and was Chief Cardiovascular Fellow in the Cardiovascular Division at the University of Virginia Medical Center.

Dr. Pruett is the John S. Najarian Clinical Chair of Transplantation Surgery at the University of Minnesota School of Medicine and former Charles O. Strickler Professor of Surgery and Chief of Transplantation at the University of Virginia Medical Center. Dr. Pruett is certified by the American Boards of Internal Medicine and Surgery and has subspecialty certificates in Infectious Diseases and Critical Care in addition to having completed a transplantation fellowship. His research interests have focused primary on infections in transplant recipients and, in particular, the interactions of the viral hepatides and the transplanted liver. Dr. Pruett has over 200 publications, most on transplant-related issues and infections, and has a long-standing interest in access to care in international health settings, particularly with programs in Saudi Arabia and Vietnam. Dr. Pruett is a national leader in raising awareness of organ donation, addressing ethics questions, and maximizing yield and safety of donated organs. He recently completed the leadership cycle for the United Network for Organ Sharing, including serving as President. He is a council member of the American Society of Transplant Surgeons and serves on the Transplant Advisory Committee and the American Board of Surgery and the Board of Directors of LifeNet Health. Dr. Pruett received his BS in Chemistry and Philosophy from Wheaton College and his MD from the Baylor College of Medicine after which he undertook internal medicine training at the University of Michigan and surgical residency and transplant training at the University of Minnesota.

Dr. Ruffolo is the recently retired President of Research and Development for Wyeth Pharmaceuticals, and Corporate Senior Vice President of Wyeth. In that role, he managed an R&D organization consisting of 9,000 scientists with an annual budget in excess of $3 billion. He joined Wyeth in 2000 as Executive Vice President, responsible for Pharmaceutical Research and Development, where he led the transformation of the Wyeth R&D pipeline, adding many promising new drug candidates. Prior to joining Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), where he was Senior Vice President and Director of Biological Sciences, Worldwide. Before joining SmithKline Beecham, Dr. Ruffolo spent six years at Lilly Research Laboratories, where he was Chairman of the Cardiovascular Research Committee. During his career in the pharmaceutical industry, Dr. Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including Carvedilol (Coreg/Kredex/Dilatrend) for the treatment of congestive heart failure, acute myocardial infarction, and hypertension, Ropinerole (Requip) for Parkinson's disease, Dobutamine (Dobutrex) for congestive heart failure, and Eprosartan (Teveten) for hypertension. Dr. Ruffolo has won numerous prestigious awards, including the 2008 Scrip Lifetime Achievement Award and the 2008 Discoverer's Award for the discovery and development of carvedilol (Coreg). Dr. Ruffolo received his BS in Pharmacy summa cum laude with Distinction, and his Ph.D. in Pharmacology, both from The Ohio State University. Thereafter, he spent two years as a postdoctoral fellow at the National Institutes of Health. He is Adjunct Professor of Pharmacology at The Ohio State University and Adjunct Professor of Physiology and Pharmacology at the West Virginia University School of Medicine. Since his retirement, Dr. Ruffolo has been involved in various philanthropic endeavors. He and his wife underwrote the complete renovation of the Robert & Stephany Ruffolo Lecture Hall in the College of Pharmacy at his alma mater, The Ohio State University, and they have established endowed scholarships and/or fellowships at The Ohio State University, West Virginia University, and the University of Florida. He also sits on the boards of directors for several biotechnology companies as well as non-profit charitable organizations.

Dr. Fisher began his career at the University of California, Davis in 1975 and progressed through several research positions in the area of inhalation toxicology. In 1980, he joined Battelle in Columbus, OH, and during his nine years there he advanced to the position of Vice President of the Health and Environmental Effects Center. From 1989 to 1992, he was Vice President of Drug Safety and Metabolism for Sandoz Research Institute in East Hanover, NJ. He joined Wyeth Pharmaceuticals in 1992 as Vice President, Drug Safety and Metabolism and was promoted to Senior Vice President in 1998. In January 2005, he assumed the role of chief preclinical scientist for Wyeth as Senior Vice President, Office of the President. Dr. Fisher has a B.A. degree from Northeastern University, an M.A. from the University of California, Santa Barbara, and a Ph.D. in Chemical Ecology from the University of California, Davis. He has published over 160 scientific papers and he is the former editor of Drug and Chemical Toxicology and a member of the editorial boards of several pharmacology and toxicology journals.